Lorcaserin Phase 3 Clinical Trial In Patients With Type 2 Diabetes Shows Statistically Significant Weight Loss
Links shared publicly online about this topic.
- 737total visits
Lorcaserin Phase 3 Clinical Trial In Patients With Type 2 Diabetes Shows Statistically Significant Weight Loss
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. reported that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and
View full resource at medicalnewstoday.com
Tags: Diabetes, Type 2 Diabetes, Obesity Medication, Weight Loss, Pharma, Phase 3 Clinical Trial, Clinical Trial, Lorcaserin
Most Recently Shared on November 11, 2010 at 4:05 am By:
Lorcaserin Phase 3 Clinical Trial In Patients With Type 2 Diabetes Shows Statistically Significant Weight Loss http://mnt.to/3MmF
Also Shared By:
Lorcaserin Phase 3 Clinical Trial in Patients with Type 2 Diabetes Shows Statistically Significant Weight Loss - Drugs.com MedNews
drugs.com — “Arena Conference Call and Webcast Scheduled for Today at 8 30 SAN DIEGO and WOODCLIFF LAKE, N.J., Nov. 9, 2010 Arena Pharmaceuticals, Inc. (Nasdaq ARNA) and Eis” View full resource at drugs.com
Most Recently Shared on November 9, 2010 at 3:21 pm By:
Drugs and Devices OW OW Health
Lorcaserin Phase 3 Clinical Trial in Patients with Type 2 Diabetes Shows Statistically Significant Weight ... http://bit.ly/czZKGP #drug
Advertisement
MNT Diabetes News
@mnt_diabetes
Lorcaserin Phase 3 Clinical Trial In Patients With Type 2 Diabetes Shows Statistically Significant Weight Loss http://mnt.to/3MmF #diabetes
1 year ago...